Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,087 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,118
- Phase 1824
- Phase 1/Phase 2483
- Phase 3349
- Phase 4127
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California405
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida111
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,087 total
- NCT04318678RecruitingPhase 1
CD123 CAR T-cell therapy for relapsed leukemia and related cancers
This early-phase study tests a lab-made immune therapy (CD123 CAR T cells) for children and young adults up to age 21 whose cancer has come back or didn’t respond to treatment. The goal is to see if these CAR T cells can find and attack cancer cells that carry a marker called CD123.
Memphis, TennesseeAges Up to 21 years - NCT04323748RecruitingPhase 1
Testing a stronger rituximab dose schedule for new ITP
This trial studies whether a “dose-dense” rituximab schedule can help children and teens with newly diagnosed, high-risk immune thrombocytopenia (ITP). It aims to raise/maintain platelet counts and control bleeding, while carefully checking safety.
Vahalla, New YorkAges 1–21 - NCT04329728RecruitingPhase 1/Phase 2
Study drug for relapsed or refractory lymphoid cancers
This Phase 1/2 study tests AVM0703 in people ages 12+ with certain lymphoid cancers that have returned or not responded to treatment. It may help shrink the cancer or control it when other treatments have failed or are not possible.
Duarte, CaliforniaAges 12–95 - NCT04330729Recruiting
Aspirin effect on blood clotting in kidney disease
This study checks how aspirin (also called salicylate) affects how platelets work, which helps blood clot. It involves people with advanced chronic kidney disease who are treated with Aranesp, and it may help guide safer care.
RoskildeAges 18–85 - NCT04332822RecruitingPhase 3
Testing mini-CHOP versus adding polatuzumab for lymphoma
This study compares two lymphoma treatments: mini-CHOP alone versus mini-CHOP plus a drug called polatuzumab vedotin. It aims to see which regimen works better and is tolerable for older or frail people with certain types of aggressive B-cell lymphoma.
AlburyAges 75 years+ - NCT04339777RecruitingPhase 2
Bone marrow transplant for inherited immune system disorders
This trial studies how well a donor bone marrow (stem cell) transplant works for people with inherited immune system problems (called immune deficiencies). It’s for patients who haven’t improved with usual treatment or don’t have another good option.
Bethesda, MarylandAges 4–69 - NCT04345081Recruiting
Compare two breast surgery skin-sparing methods and recovery
This trial compares two types of mastectomy (with skin and nipple options) and implant reconstruction to see which gives better cosmetic results, comfort, and satisfaction. You may help doctors learn which approach leads to a better quality of life after surgery.
BudapestAges 18–65 - NCT04349358Recruiting
PET/CT scan test to find bone lesions in new myeloma
This trial compares two types of PET/CT scans to see which one better finds lesions (areas of disease) in people with newly diagnosed multiple myeloma. If you qualify, you may help doctors choose the most useful scan to guide care.
BesançonAges 18–75 - NCT04356235Recruiting
Comparing immediate vs delayed breast implant reconstruction results
This study compares two timing options for rebuilding the breast with implants, looking at cosmetic results, quality of life, and patient satisfaction. It may help you understand which approach could fit you better and what to expect over follow-up time.
BudapestAges 18–65 - NCT04368702Recruiting
MRI-guided radiation for people needing radiation for cancer
This study tests whether radiation given with help from MRI (a type of scan) can better treat cancers that need radiation. You may be eligible if your cancer is confirmed and you can safely have MRI scans.
Boston, MassachusettsAges 18 years+ - NCT04370301RecruitingPhase 2
Reduced-intensity stem cell transplant with JAK inhibitor for myelofibrosis
This study tests giving a JAK inhibitor before and after a reduced-intensity stem cell transplant to treat primary or secondary myelofibrosis. The goal is to improve disease control while using a less harsh transplant approach.
Seattle, WashingtonAges 18–70 - NCT04375631RecruitingPhase 1
Study of chemo plus donor stem cell transplant for blood cancers
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
Seattle, WashingtonAges 18 years+ - NCT04378647RecruitingPhase 2
Brentuximab before transplant for relapsed CD30 Hodgkin lymphoma
This trial studies whether brentuximab vedotin given in the “second-line” setting can help people with relapsed or hard-to-treat classic Hodgkin lymphoma get ready for an autologous (your own cells) stem cell transplant. It’s specifically for tumors that test positive for CD30, and it checks safety and how well treatment works before transplant.
Barcelona, BarceolnaAges 18–65 - NCT04385290RecruitingPhase 1/Phase 2
Testing midostaurin plus gemtuzumab for newly diagnosed AML
This trial studies whether combining two medicines—midostaurin and gemtuzumab (with standard chemotherapy)—can improve outcomes for newly diagnosed acute myeloid leukemia (AML). It is testing a first-line treatment plan tailored to specific genetic changes in the leukemia.
München, BavariaAges 18–75 - NCT04390737RecruitingPhase 1/Phase 2
Study drug HH2853 for hard-to-treat lymphoma and solid cancers
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT04402086Recruiting
Rheumatology patient and skin sample registry study at Yale
This study builds a health record and blood/skin sample collection for people with rheumatic autoimmune diseases who are getting care at Yale. It may help researchers understand these conditions and develop better tests or treatments over time.
New Haven, ConnecticutAges 18–99 - NCT04414475RecruitingPhase 2
Selinexor plus low-dose steroid for hard-to-treat myeloma
This Phase 2 trial tests selinexor (a targeted anti-cancer medicine) plus low-dose dexamethasone to treat multiple myeloma that has not responded to many prior treatments. It compares selinexor combinations depending on what medicines you’ve already had, aiming to reduce myeloma activity and improve outcomes.
Pátrai, AchaiaAges 18 years+ - NCT04416178Recruiting
Survey and interviews for families affected by sickle cell disease
This study collects feedback through surveys, interviews, and focus groups from people affected by sickle cell disease. Your input helps the research team improve how genomic and gene-therapy information and needs are understood for patients and caregivers.
Memphis, TennesseeAges 13 years+ - NCT04417803Recruiting
Testing blood and tumor markers to guide lymphoma treatment
This study looks at “biomarkers” (measurable signs in your tumor and possibly blood) to understand your lymphoma’s genetic make-up. The goal is to see which markers may help doctors decide on treatment and timing.
DijonAges 18 years+ - NCT04425421Recruiting
Treatment plan for children with Burkitt lymphoma
This trial uses a recommended treatment approach for children who have Burkitt lymphoma, a specific type of blood cancer. It may help by guiding care when the full standard treatment schedule can’t be followed for every child.
OuagadougouAges Up to 18 years - NCT04440267RecruitingPhase 2
Tested leukemia treatment for mixed-type acute leukemia
This Phase 2 study tests a leukemia-based treatment for people with acute leukemia that doesn’t clearly belong to one type. It aims to improve outcomes for patients who meet specific health and heart/lab requirements.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT04442412RecruitingPhase 3
Prednisone and vitamin D before chemo for certain lymphomas
This Phase 3 study tests whether a short “pre-treatment” with prednisone, with or without vitamin D, can improve outcomes when followed by standard lymphoma chemo. It aims to see if adding vitamin D early can help older adults tolerate or benefit from treatment for specific lymphoma types.
Brescia, BSAges 65 years+ - NCT04448184RecruitingPhase 3
Platelet transfusion strategy during stem cell transplant
This trial compares how platelets are given during a stem cell transplant to help prevent bleeding. It also watches for clotting risks, since platelets can affect both bleeding and clot formation.
Calgary, AlbertaAges 18 years+ - NCT04460235RecruitingPhase 4
Compare two pneumococcal vaccines in adults treated for lymphoma
This trial compares two vaccination plans to see which one works better for preventing pneumococcal infections after lymphoma chemotherapy. You may be randomly assigned to one of the vaccine strategies, and the study checks your immune response.
AngersAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,087 recruiting hematology studies from the U.S. registry right now, out of 7,715 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.